Prasugrel as a potential cancer promoter: Review of the unpublished data

Archives of Internal Medicine

Volumn 170, Issue 12, 2010, Pages 1078-1080

  Floyd, James S ^a   Serebruany, Victor L ^b  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; PRASUGREL;

ACUTE CORONARY SYNDROME; BLEEDING; CANCER MORTALITY; CANCER RISK; CARCINOGENICITY; COLON CANCER; DOSE RESPONSE; DRUG MECHANISM; DRUG SAFETY; HEART INFARCTION; HUMAN; NONHUMAN; NOTE; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RISK REDUCTION; SOLID TUMOR; STROKE;

ACUTE CORONARY SYNDROME; HUMANS; INCIDENCE; NEOPLASMS; PERIODICALS AS TOPIC; PIPERAZINES; RECEPTORS, PURINERGIC P2; RISK FACTORS; THIOPHENES; UNITED STATES;

EID: 77954182060     PISSN: 00039926     EISSN: 15383679     Source Type: Journal    
DOI: 10.1001/archinternmed.2010.154     Document Type: Note

References (14)

1. Food and Drug Administration. New Drug Application 22-307. http://www.accessdata.fda.gov/drugsatfda-docs/nda/2009/022307s000TOC.cfm. Accessed January 7, 2010.
2. Wiviott SD, Braunwald E, McCabe CH, et al; TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357(20):2001-2015.
3. Serebruany V, Shalito I, Kopyleva O. Prasugrel development - claims and achievements. Thromb Haemost. 2009;101(1):14-22.
4. Food and Drug Administration. Briefing document, February 3, 2009 meeting of FDA Cardiovascular and Renal Drugs Advisory Committee. http://www.fda.gov/ ohrms/dockets/ac/09/briefing/2009-4412b1-01-FDA.pdf. Accessed July 14, 2009.
5. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet. 1996;348(9038):1329-1339.
6. Bhatt DL, Fox KA, Hacke W, et al; CHARISMA Investigators. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med. 2006;354(16):1706-1717.
7. Unger EF. Weighing benefits and risks - the FDA's review of prasugrel.N Engl J Med. 2009; 361(10):942-945.
8. Serebruany VL. Platelet inhibition with prasugrel and cancer risks. Am J Med. 2009;122(5):407-408.
9. Honn KV, Tang DG, Crissman JD. Platelets and cancer metastasis: a causal relationship? Cancer Metastasis Rev. 1992;11(3-4):325-351.
10. Struyf S, Burdick MD, Peeters E, et al. Platelet factor-4 variant chemokine CXCL4L1 inhibits melanoma and lung carcinoma growth and metastasis by preventing angiogenesis. Cancer Res. 2007;67(12):5940-5948.
11. McCarty OJ, Mousa SA, Bray PF, Konstantopoulos K. Immobilized platelets support human colon carcinoma cell tethering, rolling, and firm adhesion under dynamic flow conditions. Blood. 2000;96(5):1789-1797. (Pubitemid 30661063)
12. Serebruany VL, Glassman AH, Malinin AI, et al. Platelet/endothelial biomarkers in depressed patients treated with the selective serotonin reup-take inhibitor sertraline after acute coronary events: the Sertraline AntiDepressant Heart Attack Randomized Trial (SADHART) Platelet Substudy. Circulation. 2003;108(8):939-944.
13. Matetzky S, Fefer P, Shenkman B, Varon D, Savion N, Hod H. Effectiveness of reloading to overcome clopidogrel nonresponsiveness in patients with acute myocardial infarction. Am J Cardiol. 2008;102(5):524-529.
14. Khuri FR. Weighing the hazards of erythropoiesis stimulation in patients with cancer. N Engl J Med. 2007;356(24):2445-2448. (Pubitemid 46919767)